Hierarchically Engineered Nanotheranostic for Ovarian Cancer

Overview

University of New Mexico Ovarian cancer is the deadliest cancer among women. Less than one-half of patients survive for more than five years after diagnosis. After mutilating surgery women still have cancer cells left and sometimes the drugs are too weak to fight with the remaining cells. This project hypothesizes that when chemotherapeutics with different activation sites are used in co-therapy it will decrease cell viability. In addendum this study focused on hydrophobic drugs who have low bioavailability which makes it hard for them to get into the cell. This causes a lot of the chemotherapeutic to be wasted as the body will filter it out through the kidneys and liver damaging them in the process. To increase the efficiency of the hydrophobic drugs they were loaded onto nanoparticles. The nanoparticles increased the bioavailability of all the hydrophobic chemotherapeutics, decreased cell viability, and increased the co-therapy effect of hydrophobic combinations containing Afatinib. Using this treatment more women can be cured from ovarian cancer and less drug can be used to do it.

Competition history

• JSHS 2020 Category not listed

Resources

• National JSHS abstract book ↗

Related projects

Closest projects by meaning, across every fair and year in the corpus.